Cargando…
Intralesional Bevacizumab (Avastin(®)) as a Novel Addition to Infantile Hemangioma Management: A Medical Hypothesis
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Medknow Publications & Media Pvt Ltd
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5632942/ https://www.ncbi.nlm.nih.gov/pubmed/29026847 http://dx.doi.org/10.4103/jrpp.JRPP_17_38 |
| _version_ | 1783269799124533248 |
|---|---|
| author | Pourazizi, Mohsen Kabiri, Sattar Abtahi-Naeini, Bahareh |
| author_facet | Pourazizi, Mohsen Kabiri, Sattar Abtahi-Naeini, Bahareh |
| author_sort | Pourazizi, Mohsen |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-5632942 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2017 |
| publisher | Medknow Publications & Media Pvt Ltd |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-56329422017-10-12 Intralesional Bevacizumab (Avastin(®)) as a Novel Addition to Infantile Hemangioma Management: A Medical Hypothesis Pourazizi, Mohsen Kabiri, Sattar Abtahi-Naeini, Bahareh J Res Pharm Pract Letter to the Editor Medknow Publications & Media Pvt Ltd 2017 /pmc/articles/PMC5632942/ /pubmed/29026847 http://dx.doi.org/10.4103/jrpp.JRPP_17_38 Text en Copyright: © 2017 Journal of Research in Pharmacy Practice http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms. |
| spellingShingle | Letter to the Editor Pourazizi, Mohsen Kabiri, Sattar Abtahi-Naeini, Bahareh Intralesional Bevacizumab (Avastin(®)) as a Novel Addition to Infantile Hemangioma Management: A Medical Hypothesis |
| title | Intralesional Bevacizumab (Avastin(®)) as a Novel Addition to Infantile Hemangioma Management: A Medical Hypothesis |
| title_full | Intralesional Bevacizumab (Avastin(®)) as a Novel Addition to Infantile Hemangioma Management: A Medical Hypothesis |
| title_fullStr | Intralesional Bevacizumab (Avastin(®)) as a Novel Addition to Infantile Hemangioma Management: A Medical Hypothesis |
| title_full_unstemmed | Intralesional Bevacizumab (Avastin(®)) as a Novel Addition to Infantile Hemangioma Management: A Medical Hypothesis |
| title_short | Intralesional Bevacizumab (Avastin(®)) as a Novel Addition to Infantile Hemangioma Management: A Medical Hypothesis |
| title_sort | intralesional bevacizumab (avastin(®)) as a novel addition to infantile hemangioma management: a medical hypothesis |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5632942/ https://www.ncbi.nlm.nih.gov/pubmed/29026847 http://dx.doi.org/10.4103/jrpp.JRPP_17_38 |
| work_keys_str_mv | AT pourazizimohsen intralesionalbevacizumabavastinasanoveladditiontoinfantilehemangiomamanagementamedicalhypothesis AT kabirisattar intralesionalbevacizumabavastinasanoveladditiontoinfantilehemangiomamanagementamedicalhypothesis AT abtahinaeinibahareh intralesionalbevacizumabavastinasanoveladditiontoinfantilehemangiomamanagementamedicalhypothesis |